ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $77.33.

A number of equities research analysts have issued reports on ANIP shares. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Truist Financial upped their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler started coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective on the stock. Raymond James upped their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Finally, HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Natixis Advisors LLC grew its stake in shares of ANI Pharmaceuticals by 56.2% during the third quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after buying an additional 6,545 shares during the last quarter. Mizuho Markets Americas LLC bought a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $11,670,000. Victory Capital Management Inc. grew its stake in ANI Pharmaceuticals by 153.6% in the third quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock worth $771,000 after purchasing an additional 7,825 shares in the last quarter. Summit Global Investments grew its stake in ANI Pharmaceuticals by 154.2% in the third quarter. Summit Global Investments now owns 19,704 shares of the specialty pharmaceutical company’s stock worth $1,176,000 after purchasing an additional 11,952 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in ANI Pharmaceuticals by 6.9% in the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after purchasing an additional 5,829 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $58.40 on Thursday. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $1.23 billion, a P/E ratio of 49.91 and a beta of 0.71. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The business’s 50-day moving average is $58.78 and its 200 day moving average is $61.60.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The company had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm’s revenue for the quarter was up 18.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.06 earnings per share. On average, equities research analysts forecast that ANI Pharmaceuticals will post 3.51 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.